Endotoxinemia, which may happen in IBD, remains a target for inhibition with synthetic MMP inhibitors (15), but may not constitute a good indication for MMP-9 inhibition with the use of neutralizing antibodies. This evidence concerns the gene MMP9 and inflammatory bowel disease.